ClinicalTrials.gg
CompletedNCT02682381Updated Jun 9, 2021Results posted

Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

A Phase 3 interventional study of Teduglutide 0.05mg/kg and Teduglutide 0.025 mg/kg in Short Bowel Syndrome, sponsored by Shire. Completed at 27 sites in 7 countries. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
6th of 20
59 · median 20
Started
2016
with 1 other
Phase 3
16 of 20
none open now
Registered
10th of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 16 in phase 3, and was the 10th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

Teduglutide is approved for treatment of adults with short bowel syndrome (SBS). The purpose of this study is to evaluate the safety and efficacy of teduglutide in children up to the age of 17 with SBS who are dependent on parenteral support. Subjects may choose whether to receive the study drug or to participate in a standard-of-care arm. All participants who complete the study may be eligible to receive the study drug in a long-term extension study.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

Keywords

  • Teduglutide
  • pediatric
  • GLP-2
  • parenteral support
  • Short Bowel Syndrome
  • short gut syndrome
  • short gut
  • SBS
  • parenteral nutrition
04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. by a parent or guardian or emancipated minor prior to any study-related procedures
  2. When applicable, an informed assent by the subject (as deemed appropriate by the Ethics Committee/Institutional Review Board) prior to any study-related procedures
  3. Current history of SBS as a result of major intestinal resection, (eg, due to necrotizing enterocolitis, midgut volvulus, intestinal atresia, or gastroschisis)
  4. Short bowel syndrome that requires PN/IV support that provides at least 30% of caloric and/or fluid/electrolyte needs prior to screening
  5. Stable PN/IV support, defined as inability to significantly reduce PN/IV support, usually associated with minimal or no advance in enteral feeds (ie, 10% or less change in PN or advance in feeds) for at least 3 months prior to and during screening, as assessed by the investigator.
  6. Sexually active female subjects of (in the teduglutide treatment arm only) must use medically acceptable methods of during and 4 weeks after the treatment period

Exclusion criteria

Exclusion Criteria:

  1. Subjects who are not expected to be able to advance oral or tube feeding regimens
  2. Serial transverse enteroplasty or any other bowel lengthening procedure performed within 3 months of screening
  3. Known untreated intestinal obstruction contributing to feeding intolerance and inability to reduce parenteral support
  4. Unstable absorption due to cystic fibrosis or known DNA abnormalities
  5. Severe, known dysmotility syndrome, such as pseudo-obstruction or persistent, severe, active gastroschisis-related dysmotility, that is the primary contributing factor to feeding intolerance and inability to reduce parenteral support, prior to screening. Dysmotility is defined as severe if it is expected to limit the advancement of enteral feeding.
  6. Evidence of clinically significant obstruction on upper GI series done within 6 months prior to screening.
  7. Major GI surgical intervention including significant intestinal resection within 3 months prior to the screening visit (insertion of feeding tube, anastomotic ulcer repair, minor intestinal resections ≤ 10 cm, or endoscopic procedure is allowed).
  8. Unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of subjects who had undergone ventricular or atrial septal defect repair, and patent ductus arteriosus (PDA) ligation.
  9. History of cancer or clinically significant lymphoproliferative disease, not including resected cutaneous basal or squamous cell carcinoma, or in situ non aggressive and surgically resected cancer.
  10. Pregnant or lactating female subjects (in the teduglutide treatment arm only).
  11. Participation in a clinical study using an experimental drug (other than glutamine or Omegaven) within 3 months or 5.5 half-lives of the experimental drug, whichever is longer, prior to screening, and for the duration of the study.
  12. Previous use of teduglutide or native/synthetic glucagon-like peptide-2 (GLP-2)
  13. Previous use of glucagon-like peptide-1 analog or human growth hormone within 3 months prior to screening
  14. Previous use of octreotide, or dipeptidyl peptidase-4 (DPP-4) inhibitors within 3 months prior to screening
  15. Subjects with active Crohn's disease who had been treated with biological therapy (eg, antitumor necrosis factor [anti-TNF]) within the 6 months prior to the screening visit
  16. Subjects with inflammatory bowel disease (IBD) who require chronic systemic therapy that had been introduced or changed during the 3 months prior to screening
  17. More than 3 SBS-related or PN-related hospital admissions (eg, documented infection-related catheter sepsis, clots, bowel obstruction, severe water-electrolyte disturbances) within 3 months prior to the screening visit
  18. Any major unscheduled hospital admission which affects parenteral support requirements within 1 month prior to or during screening, excluding uncomplicated treatment of bacteremia, central line replacement/repair, or issues of similar magnitude in an otherwise stable subject
  19. Body weight \< 10 kg at the screening and baseline visits
  20. Signs of active severe or unstable, clinically significant hepatic impairment during the screening period, as indicated by any of the following laboratory test results :

    1. Total (TBL) ≥ 2 x (ULN)
    2. (AST) ≥ 7x ULN
    3. Alanine aminotransferase (ALT) ≥ 7x ULN

      For subjects with Gilbert's disease:

    4. Indirect (unconjugated) bilirubin ≥ 2x ULN
  21. Signs of known continuous active or unstable, clinically significant renal dysfunction shown by results of an estimated (eGFR) below 50 mL/min/1.73 m2.
  22. Parent(s) and/or subjects who are not capable of understanding or not willing to adhere to the study visit schedule and other protocol requirements
  23. Unstable, clinically significant active, untreated pancreatic or biliary disease
  24. Any condition, disease, illness, or circumstance that in the investigator's opinion puts the subject at any undue risk, prevents completion of the study, or interferes with analysis of the study results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    0.025 mg/kg/day Teduglutide

    0.025 milligrams per kilogram per day (mg/kg/day) of teduglutide for 24 weeks.

    Drug: Teduglutide 0.025 mg/kg

  • Experimental
    0.05 mg/kg/day Teduglutide

    0.05 mg/kg/day of teduglutide for 24 weeks.

    Drug: Teduglutide 0.05mg/kg

  • Active comparator
    Standard of care

    Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.

    Other: Standard of Care

Interventions

  • DrugTeduglutide 0.05mg/kg

    Drug page: Teduglutide

    0.05 mg/kg

  • DrugTeduglutide 0.025 mg/kg

    Drug page: Teduglutide

    0.025 mg/kg

  • OtherStandard of Care

    Observational cohort for the 24-week treatment period and 4 week follow-up.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24

    Reduction in weight-normalized PN/IV volume was performed using both participant diary and investigator prescribed data. Number of participants who achieved at least a 20% reduction in weight-normalized PN/IV volume between the baseline and week 24/EOT visit were reported.

    Time frame: Baseline through Week 24

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs that started or worsened on or after the date of first dose for treatment groups and those that started or worsened on or after the baseline visit for standard of care group.

    Time frame: From start of study treatment up to 28 weeks

  2. Number of Participants Who Were Completely Weaned Off Parenteral Nutrition Intravenous (PN/IV) Support at Week 24

    A participant was considered to have achieved independence from PN/IV support (completely weaned off PN/IV) if the investigator prescribed no PN/IV at EOT and there was no use of PN/IV recorded in the participant diary during the week prior to EOT.

    Time frame: Week 24

  3. Change From Baseline in Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24

    Change in PN/IV volume was reported based on the participant diary and the investigator prescribed data.

    Time frame: Baseline, Week 24

  4. Change From Baseline in Parenteral Nutrition Intravenous (PN/IV) Caloric Intake at Week 24

    Change in PN/IV caloric intake was reported based on the participant diary and the investigator prescribed data.

    Time frame: Baseline, Week 24

  5. Change From Baseline in Plasma Citrulline Levels at Week 24

    Plasma citrulline level was reported.

    Time frame: Baseline, Week 24

  6. Change From Baseline in Enteral Nutrition Volume at Week 24

    Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition volume was reported.

    Time frame: Baseline, Week 24

  7. Change From Baseline in Enteral Nutrition Caloric Intake at Week 24

    Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition caloric intake was reported.

    Time frame: Baseline, Week 24

  8. Change From Week 24 in Parenteral Nutrition Intravenous (PN/IV) Volume at Week 28

    Change in PN/IV volume was reported.

    Time frame: Week 24, Week 28

  9. Change From Week 24 in Parenteral Nutrition Intravenous (PN/IV) Caloric Intake at Week 28

    Change in PN/IV caloric intake was reported.

    Time frame: Week 24, Week 28

  10. Change From Week 24 in Plasma Citrulline Levels at Week 28

    Change in plasma citrulline level was reported.

    Time frame: Week 24, Week 28

  11. Change From Week 24 in Enteral Nutrition Volume at Week 28

    Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition volume was reported.

    Time frame: Week 24, Week 28

  12. Change From Week 24 in Enteral Nutrition Caloric Intake at Week 28

    Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition caloric intake was reported.

    Time frame: Week 24, Week 28

  13. Change From Baseline in Body Weight Z-score at Week 28

    Body weight z-score is a measure of relative weight adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.

    Time frame: Baseline, Week 28

  14. Change From Baseline in Body Height Z-score at Week 28

    Body height z-score is a measure of relative height adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.

    Time frame: Baseline, Week 28

  15. Change From Baseline in Head Circumference Z-score at Week 28

    Head circumference z-score is a measure of relative head circumference adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Head circumference was collected only for participants of less than or equal to (\<=) 36 months of age at the time of measurement.

    Time frame: Baseline, Week 28

  16. Change From Baseline in Body Mass Index (BMI) Z-score at Week 28

    BMI z-score is a measure of relative BMI adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.

    Time frame: Baseline, Week 28

  17. Change From Baseline in Participants' Stool Consistency at Week 28

    Stool consistency was assessed by typical stool form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4 - Like a sausage or snake, smooth and soft, 5 - Soft blobs with clear-cut edges, 6 - Fluffy pieces with ragged edges, a mushy stool, 7 - Watery, no solid pieces, entirely liquid.

    Time frame: Baseline, Week 28

  18. Change From Baseline in Hours Per Day of Parenteral Nutrition Intravenous (PN/IV) Support at Week 24

    The mean duration of the PN/IV infusions in hours, on the days when PN/IV was administered was reported.

    Time frame: Baseline, Week 24

  19. Change From Baseline in Days Per Week of Parenteral Nutrition Intravenous (PN/IV) Support at Week 24

    The number of days per week of PN/IV infusions were reported.

    Time frame: Baseline, Week 24

07

Results

Posted Oct 16, 2018

Participant flow

Study was conducted at 27 study centers in the United States, Belgium, Canada, the United Kingdom, Finland, Germany and Italy between 03 June 2016 (first participant first visit) and 18 August 2017 (last participant last visit).

Participant flow — Overall Study
Milestone0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Started24269
Completed24269
Not completed000

Outcome measures

PrimaryNumber of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24

Reduction in weight-normalized PN/IV volume was performed using both participant diary and investigator prescribed data. Number of participants who achieved at least a 20% reduction in weight-normalized PN/IV volume between the baseline and week 24/EOT visit were reported.

Time frame:
Baseline through Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24
Participants0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary13181
Investigator Prescribed13182
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs that started or worsened on or after the date of first dose for treatment groups and those that started or worsened on or after the baseline visit for standard of care group.

Time frame:
From start of study treatment up to 28 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Participants0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Number of Participants With Treatment-emergent Adverse Events (TEAEs)24259
SecondaryNumber of Participants Who Were Completely Weaned Off Parenteral Nutrition Intravenous (PN/IV) Support at Week 24

A participant was considered to have achieved independence from PN/IV support (completely weaned off PN/IV) if the investigator prescribed no PN/IV at EOT and there was no use of PN/IV recorded in the participant diary during the week prior to EOT.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Were Completely Weaned Off Parenteral Nutrition Intravenous (PN/IV) Support at Week 24
Participants0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Number of Participants Who Were Completely Weaned Off Parenteral Nutrition Intravenous (PN/IV) Support at Week 24230
SecondaryChange From Baseline in Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24

Change in PN/IV volume was reported based on the participant diary and the investigator prescribed data.

Time frame:
Baseline, Week 24
Reported as:
Mean · Milliliters per kilogram per day
Change From Baseline in Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24
Milliliters per kilogram per day0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary-16.16 ± 10.52-23.30 ± 17.50-6.03 ± 4.55
Investigator Prescribed-11.28 ± 15.51-22.13 ± 17.92-5.84 ± 9.80
SecondaryChange From Baseline in Parenteral Nutrition Intravenous (PN/IV) Caloric Intake at Week 24

Change in PN/IV caloric intake was reported based on the participant diary and the investigator prescribed data.

Time frame:
Baseline, Week 24
Reported as:
Mean · Kilocalories per kilogram per day
Change From Baseline in Parenteral Nutrition Intravenous (PN/IV) Caloric Intake at Week 24
Kilocalories per kilogram per day0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary-14.92 ± 8.29-18.99 ± 14.28-0.46 ± 4.95
Investigator Prescribed-11.76 ± 10.46-18.51 ± 13.22-0.27 ± 2.73
SecondaryChange From Baseline in Plasma Citrulline Levels at Week 24

Plasma citrulline level was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · Micromoles per liter
Change From Baseline in Plasma Citrulline Levels at Week 24
Micromoles per liter0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Change From Baseline in Plasma Citrulline Levels at Week 247.7 ± 8.5012.0 ± 12.000.1 ± 7.79
SecondaryChange From Baseline in Enteral Nutrition Volume at Week 24

Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition volume was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · Milliliter per kilogram per day
Change From Baseline in Enteral Nutrition Volume at Week 24
Milliliter per kilogram per day0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary7.69 ± 13.4610.96 ± 16.590.74 ± 5.91
Investigator Prescribed7.67 ± 17.778.17 ± 17.870.33 ± 0.90
SecondaryChange From Baseline in Enteral Nutrition Caloric Intake at Week 24

Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition caloric intake was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · Kilocalorie per kilogram per day
Change From Baseline in Enteral Nutrition Caloric Intake at Week 24
Kilocalorie per kilogram per day0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary8.43 ± 14.3912.98 ± 18.934.22 ± 13.75
Investigator Prescribed7.29 ± 15.8811.47 ± 21.136.66 ± 14.77
SecondaryChange From Week 24 in Parenteral Nutrition Intravenous (PN/IV) Volume at Week 28

Change in PN/IV volume was reported.

Time frame:
Week 24, Week 28
Reported as:
Mean · Milliliter per kilogram per day
Change From Week 24 in Parenteral Nutrition Intravenous (PN/IV) Volume at Week 28
Milliliter per kilogram per day0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary2.63 ± 7.801.52 ± 12.68-2.99 ± 4.94
Investigator Prescribed2.13 ± 6.95-0.35 ± 5.96-0.91 ± 2.18
SecondaryChange From Week 24 in Parenteral Nutrition Intravenous (PN/IV) Caloric Intake at Week 28

Change in PN/IV caloric intake was reported.

Time frame:
Week 24, Week 28
Reported as:
Mean · Kilocalorie per kilogram per day
Change From Week 24 in Parenteral Nutrition Intravenous (PN/IV) Caloric Intake at Week 28
Kilocalorie per kilogram per day0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary0.88 ± 2.94-0.91 ± 7.14-4.21 ± 10.30
Investigator Prescribed0.55 ± 3.420.08 ± 6.13-4.34 ± 11.22
SecondaryChange From Week 24 in Plasma Citrulline Levels at Week 28

Change in plasma citrulline level was reported.

Time frame:
Week 24, Week 28
Reported as:
Mean · Micromoles per liter
Change From Week 24 in Plasma Citrulline Levels at Week 28
Micromoles per liter0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Change From Week 24 in Plasma Citrulline Levels at Week 28-6.0 ± 9.26-9.5 ± 10.331.8 ± 6.48
SecondaryChange From Week 24 in Enteral Nutrition Volume at Week 28

Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition volume was reported.

Time frame:
Week 24, Week 28
Reported as:
Mean · Milliliter per kilogram per day
Change From Week 24 in Enteral Nutrition Volume at Week 28
Milliliter per kilogram per day0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary-0.68 ± 3.861.38 ± 8.41-0.75 ± 6.78
Investigator Prescribed1.67 ± 5.730.68 ± 6.650.39 ± 0.57
SecondaryChange From Week 24 in Enteral Nutrition Caloric Intake at Week 28

Enteral nutrition was defined as specialized formula taken orally or by tube feeding, and excluded table foods and other fluids. Change in enteral nutrition caloric intake was reported.

Time frame:
Week 24, Week 28
Reported as:
Mean · Kilocalorie per kilogram per day
Change From Week 24 in Enteral Nutrition Caloric Intake at Week 28
Kilocalorie per kilogram per day0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary-1.07 ± 4.36-0.14 ± 7.73-0.42 ± 6.13
Investigator Prescribed1.28 ± 4.30-0.11 ± 3.770.45 ± 0.64
SecondaryChange From Baseline in Body Weight Z-score at Week 28

Body weight z-score is a measure of relative weight adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.

Time frame:
Baseline, Week 28
Reported as:
Mean · Z-score
Change From Baseline in Body Weight Z-score at Week 28
Z-score0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Change From Baseline in Body Weight Z-score at Week 28-0.12 ± 0.41-0.18 ± 0.59-0.05 ± 0.37
SecondaryChange From Baseline in Body Height Z-score at Week 28

Body height z-score is a measure of relative height adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.

Time frame:
Baseline, Week 28
Reported as:
Mean · Z-score
Change From Baseline in Body Height Z-score at Week 28
Z-score0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Change From Baseline in Body Height Z-score at Week 280 ± 0.290.05 ± 0.450.16 ± 0.66
SecondaryChange From Baseline in Head Circumference Z-score at Week 28

Head circumference z-score is a measure of relative head circumference adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Head circumference was collected only for participants of less than or equal to (\<=) 36 months of age at the time of measurement.

Time frame:
Baseline, Week 28
Reported as:
Mean · Z-score
Change From Baseline in Head Circumference Z-score at Week 28
Z-score0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Change From Baseline in Head Circumference Z-score at Week 28——-0.014 ± NA
SecondaryChange From Baseline in Body Mass Index (BMI) Z-score at Week 28

BMI z-score is a measure of relative BMI adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.

Time frame:
Baseline, Week 28
Reported as:
Mean · Z-score
Change From Baseline in Body Mass Index (BMI) Z-score at Week 28
Z-score0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Change From Baseline in Body Mass Index (BMI) Z-score at Week 28-0.13 ± 0.57-0.22 ± 0.70-0.25 ± 1.42
SecondaryChange From Baseline in Participants' Stool Consistency at Week 28

Stool consistency was assessed by typical stool form based on Bristol Stool Form Scale: 1 - Separate hard lumps, hard to pass, 2 - Sausage-shaped, but lumpy, 3 - Like a sausage but with cracks on the surface, 4 - Like a sausage or snake, smooth and soft, 5 - Soft blobs with clear-cut edges, 6 - Fluffy pieces with ragged edges, a mushy stool, 7 - Watery, no solid pieces, entirely liquid.

Time frame:
Baseline, Week 28
Reported as:
Mean · Score on a scale
Change From Baseline in Participants' Stool Consistency at Week 28
Score on a scale0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Change From Baseline in Participants' Stool Consistency at Week 28-1.3 ± 1.77-1.4 ± 1.38-3.3 ± 0.35
SecondaryChange From Baseline in Hours Per Day of Parenteral Nutrition Intravenous (PN/IV) Support at Week 24

The mean duration of the PN/IV infusions in hours, on the days when PN/IV was administered was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · Hours per day (hour/day)
Change From Baseline in Hours Per Day of Parenteral Nutrition Intravenous (PN/IV) Support at Week 24
Hours per day (hour/day)0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary-2.47 ± 2.73-3.03 ± 3.84-0.21 ± 0.69
Investigator Prescribed-1.48 ± 3.59-1.79 ± 3.520.11 ± 0.33
SecondaryChange From Baseline in Days Per Week of Parenteral Nutrition Intravenous (PN/IV) Support at Week 24

The number of days per week of PN/IV infusions were reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · Days per week (Days/week)
Change From Baseline in Days Per Week of Parenteral Nutrition Intravenous (PN/IV) Support at Week 24
Days per week (Days/week)0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
Participant Diary-0.88 ± 1.78-1.34 ± 2.240 ± 0
Investigator Prescribed-0.79 ± 1.62-1.42 ± 2.320 ± 0

Adverse events

Collected over From start of study treatment up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.025 mg/kg/Day Teduglutide0/24 (0%)15/24 (62.5%)24/24 (100%)
0.05 mg/kg/Day Teduglutide0/26 (0%)20/26 (76.9%)23/26 (88.5%)
Standard of Care0/9 (0%)4/9 (44.4%)9/9 (100%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
Event0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
PyrexiaGeneral disorders4/247/261/9
DehydrationMetabolism and nutrition disorders4/240/260/9
Catheter site infectionInfections and infestations0/243/260/9
Device related infectionInfections and infestations1/243/260/9
Corona virus infectionInfections and infestations0/241/261/9
FungaemiaInfections and infestations0/240/261/9
Otitis media acuteInfections and infestations0/240/261/9
RoseolaInfections and infestations0/240/261/9
Urinary tract infectionInfections and infestations1/240/261/9
Viral infectionInfections and infestations0/242/261/9
Most frequent other events
Showing 10 of 66
Most frequent other events
Event0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of Care
VomitingGastrointestinal disorders10/248/265/9
Upper respiratory tract infectionInfections and infestations5/246/264/9
CoughRespiratory, thoracic and mediastinal disorders2/2410/263/9
DiarrhoeaGastrointestinal disorders8/242/261/9
PyrexiaGeneral disorders5/246/263/9
Alanine aminotransferase increasedInvestigations7/242/260/9
Abdominal painGastrointestinal disorders4/246/260/9
NasopharyngitisInfections and infestations4/246/262/9
Catheter site erythemaGeneral disorders0/241/262/9
Aspartate aminotransferase increasedInvestigations5/240/260/9

Baseline characteristics

Intention-to-treat (ITT) population included all enrolled participants.

Age, Continuous
Age, Continuous(Years)0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of CareTotal
Mean6.6 ± 3.616.2 ± 3.675.7 ± 4.726.3 ± 3.76
Sex: Female, Male
Sex: Female, Male(Participants)0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of CareTotal
Female87318
Male1619641
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of CareTotal
Hispanic or Latino55414
Not Hispanic or Latino1620238
Unknown or Not Reported3137
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)0.025 mg/kg/Day Teduglutide0.05 mg/kg/Day TeduglutideStandard of CareTotal
Race Customized — White1621239
Race Customized — Black or African American3317
Race Customized — Asian1113
Race Customized — American Indian or Alaska Native0000
Race Customized — Native Hawaiian or Other Pacific Islander0000
Race Customized — Other1023
Race Customized — Not allowed based on local regulations3137
08

Study locations

27 sites
  • Children's Hospital Los Angeles - RHU
    Los Angeles, California 90027, United States
  • UCLA Dept. of Medicine
    Los Angeles, California 90095, United States
  • UCSF Benioff Children's Hospital
    San Francisco, California 94158, United States
  • Georgetown Children's Research Network
    Washington, District of Columbia 20007, United States
  • Ann & Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • The Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Montefiore Medical Center Child Spc
    Bronx, New York 10467, United States
  • Children's Hospital GI Nutrition
    New York, New York 10032, United States
  • Duke Medical Center
    Durham, North Carolina 27710, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Cleveland Clinic Pediatric Specialists
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Wisconsin School of Medicine and Public Health
    Madison, Wisconsin 53792, United States
  • Cliniques Universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • Walter C. Mackenzie Health Science Center
    Edmonton, Alberta T6G 1C9, Canada
  • British Columbia Children's & Women's Hospital Center
    Vancouver, British Columbia V6H 3V4, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Helsingin yliopistollinen keskussairaala
    Helsinki, 00290, Finland
  • Universitaetsklinikum Tuebingen
    Tuebingen, Baden Wuertternberg 72076, Germany
  • Ospedale Pediatrico Bambino Gesu
    Roma, 00165, Italy
  • Great Ormond Street Hospital for Children
    London, Greater London WC1N 3JH, United Kingdom
  • Birmingham Children's Hospital
    Birmingham, B4 6NH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Aug 2017, 13 months.

Results were first posted in Oct 2018, 1 year 1 month after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 13 months is below that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2016
First posted
Feb 15, 2016
StartActual
Jun 23, 2016
Primary completionActual
Aug 18, 2017
CompletionActual
Aug 18, 2017
Results first posted
Oct 16, 2018
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02682381
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Feb 15, 2016
Start date
Jun 23, 2016
Primary completion
Aug 18, 2017
Completion
Aug 18, 2017
Results posted
Oct 16, 2018
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion